Adagio Medical Holdings, Inc (ADGM)

Over the past six months, Adagio Medical Holdings, Inc. (ADGM) stock has decreased by approximately 26.96%, with a 52-week range between $0.63 and $2.87. Key events include the release of Q1, Q2, and Q3 2025 earnings reports with negative GAAP and Non-GAAP EPS, the pricing of a private placement of securities for up to $50 million in October 2025, and the announcement of preliminary acute results and completion of enrollment in the FULCRUM-VT trial in October 2025, which showed 97% acute effectiveness and a favorable safety profile for its ultralow temperature technology.

Information regarding the specific demand seasonality for Adagio Medical Holdings, Inc.'s products and services is not available. Demand is likely driven by medical necessity, technological advancements, and regulatory approvals rather than typical seasonal consumer patterns.

Adagio Medical Holdings, Inc. (ADGM) is a medical device company focused on developing and commercializing ablation technologies for cardiac arrhythmias, operating in the Healthcare sector, specifically the Surgical and Medical Instruments industry. Their core technology is Ultra-Low Temperature Cryoablation (ULTC), and their product portfolio includes the iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories, all utilizing the same ULTC cryoablation console. The iCLAS is designed for treating atrial fibrillation and flutter, the vCLAS for ventricular arrhythmia, and the Cryopulse combines ULTC with Pulsed Field Ablation.

Adagio Medical Holdings, Inc. is headquartered in Laguna Hills, California, United States. The company is actively developing and placing its ablation technologies on the European Union (EU) market. Clinical trials for their vCLAS™ Cryoablation System have also been conducted in the U.S. and Canada.

Adagio Medical Holdings, Inc.'s brand reputation has been influenced by its clinical progress and financial performance. Positive contributions include the FDA Breakthrough Device Designation for its vCLAS™ Cryoablation System, successful clinical trial milestones for the FULCRUM-VT study, and participation in scientific symposiums. However, the company's stock price decrease and negative financial metrics indicate challenges for investor confidence.

Adagio Medical Holdings, Inc. has 20 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 11,673,026 shares. Major institutional shareholders include Perceptive Advisors Llc, Adage Capital Partners Gp, L.l.c., and Rtw Investments, Lp. As of September 30, 2024, Perceptive Advisors LLC purchased over 15 million shares, representing 76.40% of the traded stock's available shares at that time. Insiders own 0.29% of the company, while institutions own 87.46%.